| Literature DB >> 29028822 |
Min Yuan1, Susanne B Breitkopf1,2, John M Asara1,2.
Abstract
Horse urine is easily collected and contains molecules readily measurable using mass spectrometry that can be used as biomarkers representative of health, disease or drug tampering. This study aimed at analyzing microliter levels of horse urine to purify, identify and quantify proteins, polar metabolites and non-polar lipids. Urine from a healthy 12 year old quarter horse mare on a diet of grass hay and vitamin/mineral supplements with limited pasture access was collected for serial-omics characterization. The urine was treated with methyl tert-butyl ether (MTBE) and methanol to partition into three distinct layers for protein, non-polar lipid and polar metabolite content from a single liquid-liquid extraction and was repeated two times. Each layer was analyzed by high performance liquid chromatography-high resolution tandem mass spectrometry (LC-MS/MS) to obtain protein sequence and relative protein levels as well as identify and quantify small polar metabolites and lipids. The results show 46 urine proteins, many related to normal kidney function, structural and circulatory proteins as well as 474 small polar metabolites but only 10 lipid molecules. Metabolites were mostly related to urea cycle and ammonia recycling as well as amino acid related pathways, plant diet specific molecules, etc. The few lipids represented triglycerides and phospholipids. These data show a complete mass spectrometry based-omics characterization of equine urine from a single 333 μL mid-stream urine aliquot. These omics data help serve as a baseline for healthy mare urine composition and the analyses can be used to monitor disease progression, health status, monitor drug use, etc.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29028822 PMCID: PMC5640239 DOI: 10.1371/journal.pone.0186258
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1The workflow of the serial-omics analysis of horse urine from collection and MTBE extraction through high resolution tandem mass spectrometry (LC-MS/MS) analysis.
Each phase of the MTBE extraction is used for either proteomics, metabolomics or lipidomics analyses using untargeted or targeted mass spectrometry in order to gather the—omics profile.
Equine mare urine proteins identified by LC-MS/MS from a serial-omics liquid-liquid extraction.
| Protein name | Accession | MW | # of spectra |
|---|---|---|---|
| Uromodulin OS = Equus caballus | F7BM54_HORSE | 70 kDa | 376 |
| Calcium-activated chloride channel regulator 1 OS = Equus caballus | CLCA1_HORSE | 100 kDa | 101 |
| Keratin, type I cytoskeletal 10 OS = Equus caballus | F6WDW3_HORSE | 43 kDa | 66 |
| Protein AMBP OS = Equus caballus | F6UZH0_HORSE | 39 kDa | 56 |
| Immmunoglobulin lambda light chain OS = Equus caballus | F6QAU5_HORSE | 11 kDa | 47 |
| Keratin, type II cytoskeletal 1 OS = Equus caballus | F7B7X0_HORSE | 66 kDa | 44 |
| Kininogen-1 OS = Equus caballus | F7C0Z0_HORSE | 72 kDa | 42 |
| Keratin, type II cytoskeletal 5 OS = Equus caballus | F6W7V0_HORSE | 62 kDa | 33 |
| Cadherin 1 OS = Equus caballus | F6Y0D9_HORSE | 89 kDa | 26 |
| Poly-Ig receptor OS = Equus caballus | F6W2K5_HORSE | 83 kDa | 26 |
| EGF-containing fibulin-like extracellular matrix protein 1 OS = Equus caballus | F6PVG3_HORSE | 55 kDa | 25 |
| Cytokeratin-2e OS = Equus caballus | F6SHJ8_HORSE | 61 kDa | 24 |
| Pro-epidermal growth factor OS = Equus caballus | F7B762_HORSE | 133 kDa | 23 |
| Keratin, type II cytoskeletal 6A OS = Equus caballus | F7AGY4_HORSE | 60 kDa | 21 |
| Keratin, type I cytoskeletal 16 OS = Equus caballus | F6ZEQ3_HORSE | 51 kDa | 20 |
| Ubiquitin A-52 residue ribosomal protein fusion product 1 OS = Equus caballus | A0A0B4J1C5_HORSE | 15 kDa | 19 |
| Pantetheinase OS = Equus caballus | F6Z129_HORSE | 58 kDa | 17 |
| Antithrombin protein OS = Equus caballus | F7CYR1_HORSE | 52 kDa | 17 |
| Trypsinogen OS = Equus caballus | F6VNT7_HORSE | 26 kDa | 16 |
| Epithelial cell adhesion molecule OS = Equus caballus | F6R6Z6_HORSE | 33 kDa | 16 |
| Keratin, type II cytoskeletal 73 OS = Equus caballus | F7C7Y1_HORSE | 59 kDa | 16 |
| Cadherin-6 OS = Equus caballus | F6X200_HORSE | 88 kDa | 14 |
| Corticosteroid-binding globulin OS = Equus caballus | F7DRS2_HORSE | 45 kDa | 14 |
| Complement C4-A OS = Equus caballus | F6XSF7_HORSE | 193 kDa | 13 |
| Heparan sulfate proteoglycan 2 OS = Equus caballus | F7C0I7_HORSE | 466 kDa | 12 |
| Butyrophilin-like protein 10 OS = Equus caballus | F6VGK4_HORSE | 51 kDa | 12 |
| Collagen alpha-3(VI) chain OS = Equus caballus | F6R735_HORSE | 342 kDa | 11 |
| IgG heavy chain OS = Equus caballus | H9GZT5_HORSE | 36 kDa | 11 |
| Cadherin-15 OS = Equus caballus | F6WEI6_HORSE | 82 kDa | 11 |
| Tenascin-X OS = Equus caballus | F7CCQ6_HORSE | 445 kDa | 9 |
| Desmocollin-2 OS = Equus caballus | F6UVP2_HORSE | 100 kDa | 8 |
| Keratin, type I cytoskeletal 17 OS = Equus caballus | F6YIA9_HORSE | 48 kDa | 8 |
| Mucin-5AC OS = Equus caballus | F6QC83_HORSE | 477 kDa | 7 |
| Aminopeptidase N OS = Equus caballus | F7B847_HORSE | 110 kDa | 6 |
| Major allergen Equ c 1 OS = Equus caballus | ALL1_HORSE | 22 kDa | 6 |
| Cartilage intermediate layer protein OS = Equus caballus | F7C2J3_HORSE | 133 kDa | 5 |
| Tetratricopeptide repeat protein 28 OS = Equus caballus | F6WBY4_HORSE | 257 kDa | 5 |
| Protein FAM151A OS = Equus caballus | F6WIV4_HORSE | 64 kDa | 4 |
| Serum albumin OS = Equus caballus | ALBU_HORSE | 69 kDa | 4 |
| Microtubule-actin cross-linking factor 1 OS = Equus caballus | F6YMD9_HORSE | 827 kDa | 3 |
| Collagen alpha-1 type I chain OS = Equus caballus | F7A3F7_HORSE | 141 kDa | 3 |
| Nuclear receptor co-repressor 2 OS = Equus caballus | F6UWM2_HORSE | 275 kDa | 3 |
| Synapsin-1 isoform Ib OS = Equus caballus | F6XVE9_HORSE | 58 kDa | 3 |
| AXL receptor tyrosine kinase OS = Equus caballus | F6VEV4_HORSE | 98 kDa | 3 |
| Nuclear receptor-interacting protein 1 OS = Equus caballus | F6QWB9_HORSE | 127 kDa | 3 |
| Far upstream element-binding protein 2 OS = Equus caballus | F7A984_HORSE | 70 kDa | 3 |
Fig 2A) Omics results from the urinary tract and specimen cup to the number of unique molecules identified from horse urine. A scatterplot showing the molecular weight distribution of lipids, metabolites and proteins. Reprinted from The Merck Manual for Pet Health under a CC BY license, with permission from Merck & Co., original copyright 2017. B) The ratio of metabolite:protein:lipid was approximately 10.0:1.0:0.22. The majority of urine content is small polar molecules (474) followed by a significant amount of proteins (46) and very low number of lipids (10). A short list of some example questions that can be addressed using a serial-omics approach from accessible bodily fluids such as urine, blood, etc.
Fig 3Biological pathways represented by serial-omics of healthy horse mare urine.
A) Panther biological processes from proteomics data analysis. B) MetaboAnalyst metabolite enrichemnt sets from polar metabolomics data. C) The few identified lipids were represented by triglycerides and glycerophospholipids. D) Plant metabolites identified as horse diet specific.
Top 60 equine mare urine metabolites by intensity from 474 total identified metabolites by LC-MS/MS from a serial-omics liquid-liquid extraction.
| Hippuric acid | HMDB00714 | C9H9NO3 | 11.8 |
| Phenylacetylglycine | HMDB00821 | C10H11NO3 | 11.6 |
| 2-Hydroxy-4-trifluoromethyl benzoic acid | HMDB60715 | C8H5F3O3 | 11.6 |
| Creatinine | HMDB00562 | C4H7N3O | 11.4 |
| p-Cresol glucuronide | HMDB11686 | C13H16O7 | 11.3 |
| Buntansin A | HMDB35086 | C11H 8O5 | 10.9 |
| Acetohydroxamic Acid | HMDB14691 | C2H5NO2 | 10.8 |
| Mesoridazine | HMDB15068 | C21H26N2OS2 | 10.7 |
| Mammeigin | HMDB30785 | C25H24O5 | 10.6 |
| Monomethyl phenylphosphonate | HMDB31868 | C7H9O3P | 10.6 |
| Neoisoliquiritin | HMDB37317 | C21H22O9 | 10.5 |
| Geranylgeranylcysteine | HMDB11678 | C23H37NO3S | 10.4 |
| 4-Hydroxy-8-methoxy-2H-furo[2,3-h]-1-benzopyran-2-one | HMDB32659 | C12H8O5 | 10.4 |
| N'-Hydroxysaxitoxin | HMDB33664 | C10H17N7O5 | 10.4 |
| 4-Hydroxyphenyl-2-propionic acid | HMDB41683 | C9H10O3 | 10.4 |
| cis-Mulberroside A | HMDB31726 | C26H32O14 | 10.3 |
| N-Methylphthalimide | CASNO:550-44-7 | C9H7NO2 | 10.3 |
| Phlorizin | HMDB36634 | C21H24O10 | 10.3 |
| L-leucyl-L-proline | HMDB11175 | C11H20N2O3 | 10.2 |
| Benzocaine | HMDB04992 | C9H11NO2 | 10.2 |
| Vanilloloside | HMDB32013 | C14H20O8 | 10.2 |
| apo-[3-methylcrotonoyl-CoA:carbon-dioxide ligase (ADP-forming)] | HMDB59607 | C7H15N3O2 | 10.1 |
| Trimethylamine N-oxide | HMDB00925 | C3H9NO | 10.1 |
| Acetaminophen | HMDB01859 | C8H9NO2 | 10.1 |
| D-(-)-Isoascorbic acid | CASNO:89-65-6 | C6H8O6 | 10.1 |
| Butyrylcarnitine | HMDB02013 | C11H21NO4 | 10.1 |
| DOPA sulfate | HMDB02028 | C9H11NO7S | 10.0 |
| Pilocarpine | HMDB15217 | C11H16N2O2 | 10.0 |
| Pyrogallol-2-O-glucuronide | HMDB60017 | C12H14O9 | 10.0 |
| 2-Hydroxy-2-methylbutanedioic acid | C02612 | C5H8O5 | 7.7 |
| citrate | C00158 | C6H8O7 | 7.3 |
| 2-Isopropylmalic acid | C02504 | C7H12O5 | 7.3 |
| 1-Methyl-Histidine | C01152 | C7H11N3O2 | 7.3 |
| betaine | C00719 | C5H11NO2 | 7.2 |
| aconitate | C00417 | C6H6O6 | 7.1 |
| oxaloacetate | C00036 | C4H4O5 | 7.1 |
| Acetylcarnitine DL | C02571 | C9H18NO4 | 7.1 |
| allantoin | C01551 | C4H6N4O3 | 7.1 |
| Urea | C00086 | CH4N2O | 6.9 |
| Acetyllysine | C02727 | C8H16N2O3 | 6.8 |
| N6-Acetyl-L-lysine | C02727 | C8H16N2O3 | 6.7 |
| 2-hydroxygluterate | C02630 | C5H8O5 | 6.7 |
| D-sedoheptulose-1-7-phosphate | C05382 | C7H15O10P | 6.6 |
| Phenylpropiolic acid | HMDB00563 | C9H6O2 | 6.6 |
| DL-Pipecolic acid | C00408 | C6H11NO2 | 6.5 |
| Citraconic acid | C02226 | C5H6O4 | 6.5 |
| Ascorbic acid | C00072 | C6H8O6 | 6.5 |
| 3-hydroxybuteric acid | C01089 | C4H8O3 | 6.5 |
| Ng,NG-dimethyl-L-arginine | C03626 | C8H18N4O2 | 6.3 |
| Kynurenic acid | C01717 | C10H7NO3 | 6.3 |
| p-hydroxybenzoate | C00156 | C7H6O3 | 6.3 |
| taurine | C00245 | C2H7NO3S | 6.2 |
| succinate | C00042 | C4H6O4 | 6.2 |
| Aminoadipic acid | C00956 | C6H11NO4 | 6.2 |
| Atrolactic acid | HMDB00475 | C9H10O3 | 6.2 |
| pantothenate | C00864 | C9H17NO5 | 6.1 |
| 2-dehydro-D-gluconate | C00629 | C6H10O7 | 6.1 |
| orotate | C00295 | C5H4N2O4 | 6.1 |
| glutamine | C00064 | C5H10N2O3 | 6.1 |
Equine mare urine non-polar lipids identified by LC-MS/MS from a serial-omics liquid-liquid extraction.
| Lipid name | Accession | Ion Formula | MS1 Log10 Peak Area |
|---|---|---|---|
| PA(16:0/18:1)-H | LMGP10010032 | C37H70O8N0P1 | 7.473 |
| PA(18:0/18:1)-H | LMGP10010037 | C39H74O8N0P1 | 6.740 |
| PE(16:0/16:0)+H | LMGP02010037 | C37H75O8N1P1 | 6.842 |
| PE(18:0/16:0)+H | LMGP02011205 | C39H79O8N1P1 | 6.407 |
| PEt(16:0/14:0)-H | N/A | C35H68O8N0P1 | 6.613 |
| TG(16:0/14:0/16:0)+NH4 | LMGL03012786 | C49H98O6N1 | 6.224 |
| TG(16:0/16:0/16:0)+NH4 | LMGL03010001 | C51H102O6N1 | 6.480 |
| TG(18:0/16:0/16:0)+NH4 | LMGL03010004 | C53H106O6N1 | 6.213 |
| TG(16:0/18:1/18:1)+NH4 | LMGL03010100 | C55H106O6N1 | 6.415 |
| TG(18:1/18:1/18:1)+NH4 | LMGL03012612 | C57H108O6N1 | 6.402 |